Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.
Clin J Am Soc Nephrol. 2024 Aug 1;19(8):1005-1015. doi: 10.2215/CJN.0000000000000474. Epub 2024 Jun 7.
C3 glomerulopathy (C3G), which encompasses C3GN and dense deposit disease (DDD), results from dysregulation of the alternative complement pathway. Data on disease recurrence after kidney transplantation are limited, and details on histologic features of recurrent C3G are scarce. We aimed to evaluate C3G recurrence in the allograft, with a focus on histologic presentation and progression.
We retrospectively analyzed 18 patients with native kidney failure attributed to C3G (12 C3GN and six DDD), who received a kidney transplant from January 2016 to January 2023. Demographic, genetic, clinical, and histologic data were studied. The NanoString 770 genes PanCancer Immune Profiling Panel was used for transcriptomic analysis. Disease recurrence was the primary outcome.
During a median (interquartile range) follow-up period of 37 (18–56) months, C3G recurrence occurred in 16 (89%) patients (11 with C3GN and five with DDD) at a median (interquartile range) of 33 (13–141) days after transplantation. Over a third (38%) of recurrent cases were detected in protocol biopsies, and only 31% of patients presented with >300 mg/g of proteinuria. Recurrence in index biopsies was mainly established through a combination of immunofluorescence and electron microscopy findings, while it showed only subtle histologic alterations and no characteristic transcriptomic signals. Over time, histologic chronicity indices increased, but all the allografts were functioning at the end of follow-up. Patients with recurrence of C3GN and DDD showed overlapping immunofluorescence and electron microscopy findings and had similar recurrence rate and time to recurrence.
Most of the patients with native kidney failure attributed to C3G developed disease recurrence very early after kidney transplantation, usually with minimal proteinuria, mild histologic alterations, and favorable short-term allograft survival. Immunofluorescence and electron microscopy played a crucial role in detecting early, subclinical recurrence of C3GN and DDD, which showed significant overlapping features.
C3 肾小球病(C3G)包括 C3GN 和致密沉积物病(DDD),是由于替代补体途径失调引起的。关于肾移植后疾病复发的数据有限,关于复发性 C3G 的组织学特征的细节也很少。我们旨在评估同种异体移植中 C3G 的复发情况,重点关注组织学表现和进展。
我们回顾性分析了 18 名因 C3G 导致原发性肾病衰竭的患者(12 名 C3GN 和 6 名 DDD),他们于 2016 年 1 月至 2023 年 1 月接受了肾移植。研究了人口统计学、遗传学、临床和组织学数据。使用 NanoString 770 基因 PanCancer 免疫分析小组进行转录组分析。疾病复发是主要结局。
在中位(四分位间距)37(18-56)个月的随访期间,16(89%)名患者(11 名 C3GN 和 5 名 DDD)在移植后中位(四分位间距)33(13-141)天发生 C3G 复发。超过三分之一(38%)的复发病例在方案活检中检测到,只有 31%的患者出现>300mg/g 的蛋白尿。索引活检中的复发主要通过免疫荧光和电子显微镜检查结果的结合来确定,而这些结果仅显示出轻微的组织学改变,没有特征性的转录组信号。随着时间的推移,组织学慢性指数增加,但所有的同种异体移植物在随访结束时都在发挥功能。C3GN 和 DDD 复发患者的免疫荧光和电子显微镜检查结果有重叠,复发率和复发时间相似。
大多数因 C3G 导致原发性肾病衰竭的患者在肾移植后非常早期就出现疾病复发,通常伴有轻微的蛋白尿、轻微的组织学改变和良好的短期同种异体移植物存活。免疫荧光和电子显微镜在检测 C3GN 和 DDD 的早期亚临床复发方面发挥了关键作用,这些复发表现出显著的重叠特征。